Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage Ⅲ gastric cancer as adjuvant setting
Stomach Cancer
DRUG: nab paclitaxel|DRUG: Tegafur|DRUG: Oxaliplatin|DRUG: Capecitabine
3 years Diseases-free Survival rate(3 years-DFS), DFS is defined as time from the date of inclusion up to the date of disease progression or death, up to 3 years
Overall survival (OS), Overall survival is defined as time from the start of treatment until death due to any reason., up to 3 years|Safety as measured by number and grade of adverse events, Summary adverse events according to NCI-CTCAE 5.0, up to 3 years
This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage Ⅲ gastric cancer as adjuvant setting. The primary endpoint is the 3-year diseases-free survival (DFS) rate. The secondary endpoints are the overall survival (OS) and safety.